Cutaneous staining for Fibrosis is made Faster with Collagen Hybridizing Peptides
Introduction
Dermatitis is a broad term containing various subtypes of skin inflammation. Common symptoms include red, dry, and itching skin. Many subtypes have high heterogeneity, in that individual trajectories are unpredictable. Complications may include asthma, hay fever, bacterial and viral skin infections, sleep loss, and eye problems. Genetics, barrier function, immunity, and environmental factors all serve key roles in these disease’s development. Unfortunately, such inclusion of a multitude of elements in its pathogenesis, creates challenging means to successful treatment.
Current Treatment Challenges
Dermatitis’s consideration as a mere skin disorders results in anti-inflammatory therapy of disease flares as its first-line of treatment.These include various topical corticosteroids(TCSs), topical calcineurin inhibitors, and as of recently a phosphodiesterase 4(PDE4) inhibitor. Despite recent advancements, therapeutic armamentarium remains limited, and disease management of Dermatitis is said to follow a ‘one-size-fits-all’ model -- in which side effects such as thinning skin, acne, and changes in skin color are common.
Why CHPs?
The body’s reaction to inflammation initiates collagen synthesis, to repair damaged tissues. By leveraging our Collagen Hybridizing Peptides, 3Helix is at the forefront of advancing the understanding and treatment of skin inflammation. Our innovations provide a new pathway for researchers to monitor and potentially reverse Dermatitis, offering hope for hundreds of millions affected by this inflammatory disease.
